Researchers have claimed one of China’s key COVID-19 vaccine candidate, dubbed as BBIBP-CorV, was showing promising results of its clinical tests.
The vaccine, developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG), was found to be safe and has been approved for emergency use in the country.CNBG conducted Phase I and Phase II of the vaccine clinical tests, which involved more than 600 healthy participants, between April 29 and July 30 and the result showed that the vaccine triggered immune responses in a combined early and mid-stage test in humans.
Read more on toopanda.com